Complement modulation in solid-organ transplantation

Transplantation Reviews

Volumn 28, Issue 3, 2014, Pages 119-125

  Touzot, Maxime ^a,b   Obada, Erika Nnang ^a   Beaudreuil, Severine ^a,b   François, Hélène ^a,b   Durrbach, Antoine ^a,b  

^a Neuroradiology   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4D; ECULIZUMAB; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY MEDIATED REJECTION; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL PRACTICE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; HUMAN; INNATE IMMUNITY; MOLECULE; NONHUMAN; ORGAN TRANSPLANTATION; REGULATORY MECHANISM; REVIEW; SOLID ORGAN TRANSPLANTATION; HISTOCOMPATIBILITY; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; ORGAN TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 84903638209     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2014.03.001     Document Type: Review

References (111)

1. Ricklin D., Hajishengallis G., Yang K., et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
2. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171:715-727.
3. Andrews P.A., Finn J.E., Lloyd C.M., et al. Expression and tissue localization of donor-specific complement C3 synthesized in human renal allografts. Eur J Immunol 1995, 25:1087-1093.
4. Farrar C.A., Zhou W., Lin T., et al. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J 2006, 20:217-226.
5. Welch T.R., Beischel L.S., Witte D.P. Differential expression of complement C3 and C4 in the human kidney. J Clin Invest 1993, 92:1451-1458.
6. Tang S., Zhou W., Sheerin N.S., et al. Contribution of renal secreted complement C3 to the circulating pool in humans. J Immunol 1999, 162:4336-4341.
7. Naesens M., Li L., Ying L., et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol 2009, 20:1839-1851.
8. Peng Q., Li K., Smyth L.A., et al. C3a and C5a promote renal ischemia-reperfusion injury. J Am Soc Nephrol 2012, 23:1474-1485.
9. Mizuno M., Blanchin S., Gasque P., et al. High levels of complement C3a receptor in the glomeruli in lupus nephritis. Am J Kidney Dis 2007, 49:598-606.
10. Bao L., Osawe I., Haas M., et al. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005, 175:1947-1955.
11. Braun M.C., Reins R.Y., Li T.-B., et al. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 2004, 173:4190-4196.
12. Passwell J., Schreiner G.F., Nonaka M., et al. Local extrahepatic expression of complement genes C3, factor B, C2, and C4 is increased in murine lupus nephritis. J Clin Invest 1988, 82:1676-1684.
13. Pratt J.R., Basheer S.A., Sacks S.H. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002, 8:582-587.
14. Pickering M.C., Cook H.T., Warren J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002, 31:424-428.
15. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 2008, 6:132-142.
16. Harboe M., Mollnes T.E. The alternative complement pathway revisited. J Cell Mol Med 2008, 12:1074-1084.
17. Nangaku M. Complement regulatory proteins in glomerular diseases. Kidney Int 1998, 54:1419-1428.
18. Yamada K., Miwa T., Liu J., et al. Critical protection from renal ischemia reperfusion injury by CD55 and CD59. J Immunol 2004, 172:3869-3875.
19. Ichida S., Yuzawa Y., Okada H., et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994, 46:89-96.
20. Lesher A.M., Song W.-C. Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) 2010, 15:663-675.
21. Zhang M., Alicot E.M., Chiu I., et al. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006, 203:141-152.
22. Busche M.N., Pavlov V., Takahashi K., et al. Myocardial ischemia and reperfusion injury is dependent on both IgM and mannose-binding lectin. Am J Physiol Heart Circ Physiol 2009, 297:H1853-H1859.
23. Castellano G., Melchiorre R., Loverre A., et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol 2010, 176:1648-1659.
24. De Vries B., Köhl J., Leclercq W.K.G., et al. Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils. J Immunol 2003, 170:3883-3889.
25. De Vries B., Walter S.J., Peutz-Kootstra C.J., et al. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischemia-reperfusion injury. Am J Pathol 2004, 165:1677-1688.
26. Liaño F., Gallego A., Pascual J., et al. Prognosis of acute tubular necrosis: an extended prospectively contrasted study. Nephron 1993, 63:21-31.
27. Feucht H.E., Schneeberger H., Hillebrand G., et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993, 43:1333-1338.
28. Collins A.B., Schneeberger E.E., Pascual M.A., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10:2208-2214.
29. Behr T.M., Feucht H.E., Richter K., et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999, 18:904-912.
30. Magro C.M., Pope Harman A., Klinger D., et al. Use of C4d as a diagnostic adjunct in lung allograft biopsies. Am J Transplant 2003, 3:1143-1154.
31. Fayek S.A. The value of C4d deposit in post liver transplant liver biopsies. Transpl Immunol 2012, 27:166-170.
32. Mauiyyedi S., Pelle P.D., Saidman S., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001, 12:574-582.
33. Loupy A., Hill G.S., Suberbielle C., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011, 11:56-65.
34. Lefaucheur C., Loupy A., Vernerey D., et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013, 381:313-319.
35. Pei R., Lee J.-H., Shih N.-J., et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003, 75:43-49.
36. Tait B.D., Süsal C., Gebel H.M., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013, 95:19-47.
37. Bachelet T., Couzi L., Lepreux S., et al. Kidney intragraft donor-specific antibodies as determinant of antibody-mediated lesions and poor graft outcome. Am J Transplant 2013, 13:2855-2864.
38. Lefaucheur C., Loupy A., Hill G.S., et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010, 21:1398-1406.
39. Schnaidt M., Weinstock C., Jurisic M., et al. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation 2011, 92:510-515.
40. Weinstock C., Schnaidt M. The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet 2013, 40:171-177.
41. Gebel H.M., Nickerson P.W., Zachary A.A., et al. Consensus Guidelines on the Testing and Clinical Management Issues Associated With HLA and Non-HLA Antibodies in Transplantation 2013, 95:19-47.
42. Guidicelli G., Anies G., Bachelet T., et al. The complement interference phenomenon as a cause for sharp fluctuations of serum anti-HLA antibody strength in kidney transplant patients. Transpl Immunol 2013, 29:17-21.
43. Loupy A., Lefaucheur C., Vernerey D., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013, 369:1215-1226.
44. Albrecht E.A., Ward P.A. Complement-induced impairment of the innate immune system during sepsis. Curr Allergy Asthma Rep 2004, 4:359-364.
45. Monsinjon T., Gasque P., Chan P., et al. Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J 2003, 17:1003-1014.
46. Albrecht E.A., Chinnaiyan A.M., Varambally S., et al. C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol 2004, 164:849-859.
47. Saadi S., Holzknecht R.A., Patte C.P., et al. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995, 182:1807-1814.
48. Nagayasu T., Saadi S., Holzknecht R.A., et al. Expression of tissue factor and tissue factor pathway inhibitor in porcine endothelium in response to natural antibody and complement. Transplant Proc 2001, 33:788.
49. Pratt J.R., Hibbs M.J., Laver A.J., et al. Effects of complement inhibition with soluble complement receptor-1 on vascular injury and inflammation during renal allograft rejection in the rat. Am J Pathol 1996, 149:2055-2066.
50. Pruitt S.K., Bollinger R.R. The effect of soluble complement receptor type 1 on hyperacute allograft rejection. J Surg Res 1991, 50:350-355.
51. Khan M.A., Maasch C., Vater A., et al. Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A 2013, 110:6061-6066.
52. Weiser M.R., Williams J.P., Moore F.D., et al. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996, 183:2343-2348.
53. Klaus G.G., Pepys M.B., Kitajima K., et al. Activation of mouse complement by different classes of mouse antibody. Immunology 1979, 38:687-695.
54. Peng Q., Li K., Anderson K., et al. Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction. Blood 2008, 111:2452-2461.
55. Peng Q., Li K., Patel H., et al. Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J Immunol 2006, 176:3330-3341.
56. Li F., Zhang X., Jin Y.-P., et al. Antibody ligation of human leukocyte antigen class I molecules stimulates migration and proliferation of smooth muscle cells in a focal adhesion kinase-dependent manner. Hum Immunol 2011, 72:1150-1159.
57. Carroll M.C. The complement system in regulation of adaptive immunity. Nat Immunol 2004, 5:981-986.
58. Dempsey P.W., Allison M.E., Akkaraju S., et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
59. Van der Touw W., Cravedi P., Kwan W., et al. Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. J Immunol 2013, 190:5921-5925.
60. + regulatory T cells. Nat Immunol 2013, 14:162-171.
61. Strainic M.G., Liu J., Huang D., et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008, 28:425-435.
62. Bannett A.D., McAlack R.F., Morris M., et al. ABO incompatible renal transplantation: a qualitative analysis of native endothelial tissue ABO antigens after transplantation. Transplant Proc 1989, 21:783-785.
63. Koch C.A., Khalpey Z.I., Platt J.L. Accommodation: preventing injury in transplantation and disease. J Immunol 2004, 172:5143-5148.
64. Gloor J.M., Lager D.J., Fidler M.E., et al. A Comparison of Splenectomy versus Intensive Posttransplant Antidonor Blood Group Antibody Monitoring without Splenectomy in ABO-Incompatible Kidney Transplantation. Transplantation 2005, 80:1572-1577.
65. Tobian A.R., Shirey R.S., Montgomery R., et al. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008, 48:2453-2460.
66. Tobian A.R., Shirey R.S., Montgomery R., et al. ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010, 10:1247-1253.
67. Toki D., Ishida H., Setoguchi K. Acute Antibody-Mediated Rejection in Living ABO-Incompatible Kidney Transplantation: Long-Term Impact and Risk Factors. Am J Transplant 2009, 9:567-577.
68. Shirakawa H., Ishida H., Shimizu T., et al. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience. Clin Transplant 2011, 25:878-884.
69. Wang N., Lee J.M., Tobiasch E., et al. Induction of xenograft accommodation by modulation of elicited antibody responses1 2. Transplantation 2002, 74:334-345.
70. Wang H., Arp J., Liu W., et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179:4451-4463.
71. Rother R.P., Arp J., Jiang J., et al. C5 blockade with conventional immunosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008, 8:1129-1142.
72. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984, 160:1558-1578.
73. Shimizu I., Smith N.R., Zhao G., et al. Decay-accelerating factor prevents acute humoral rejection induced by low levels of anti-alphaGal natural antibodies. Transplantation 2006, 81:95-100.
74. Pavlov V., Raedler H., Yuan S., et al. Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection. J Immunol 2008, 181:4580-4589.
75. González-Stawinski G.V., Tan C.D., Smedira N.G., et al. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection. J Heart Lung Transplant 2008, 27:357-361.
76. Tan C.D., Sokos G.G., Pidwell D.J., et al. Correlation of donor-specific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant 2009, 9:2075-2084.
77. Brodsky S.V., Nadasdy G.M., Pelletier R., et al. Expression of the decay-accelerating factor (CD55) in renal transplants-a possible prediction marker of allograft survival. Transplantation 2009, 88:457-464.
78. Chen Song S., Zhong S., Xiang Y., et al. Complement inhibition enables renal allograft accommodation and long-term engraftment in presensitized nonhuman primates. Am J Transplant 2011, 11:2057-2066.
79. Griesemer A.D., Okumi M., Shimizu A., et al. Upregulation of CD59: potential mechanism of accommodation in a large animal model. Transplantation 2009, 87:1308-1317.
80. Kinderlerer A.R., Pombo Gregoire I., Hamdulay S.S., et al. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood 2009, 113:1598-1607.
81. Salama A.D., Delikouras A., Pusey C.D., et al. Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001, 1:260-269.
82. Rother R.P., Rollins S.A., Mojcik C.F., et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
83. Forneris F., Ricklin D., Wu J., et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010, 330:1816-1820.
84. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006, 355:1233-1243.
85. Legendre C.M., Licht C., Muus P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
86. Zuber J., Fakhouri F., Roumenina L.T., et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657.
87. Fakhouri F., Frémeaux-Bacchi V., Noël L.-H., et al. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010, 6:494-499.
88. Stegall M.D., Diwan T., Raghavaiah S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11:2405-2413.
89. Kocak B., Arpali E., Demiralp E., et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013, 45:1022-1025.
90. Locke J.E., Magro C.M., Singer a L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009, 9:231-235.
91. Stewart Z., Collins T.E., Schlueter A.J., et al. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant. Transplant Proc 2012, 44:3033-3036.
92. González-Roncero F., Suñer M., Bernal G., et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012, 44:2690-2694.
93. Noone D., Al-Matrafi J., Tinckam K., et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012, 12:2546-2553.
94. Biglarnia A.-R., Nilsson B., Nilsson T., et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int 2011, 24:e61-e66.
95. Mengel M., Sis B, Haas M., et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transpl 2012, 12:563-570.
96. Bentall A., Cornell L.D., Gloor J.M., et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013, 13:76-85.
97. El Ters M., Grande J.P., Keddis M.T., et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013, 13:2334-2341.
98. Hirohashi T., Uehara S., Chase C.M., et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010, 10:510-517.
99. Sis B., Jhangri G.S., Bunnag S., et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009, 9:2312-2323.
100. Hidalgo L.G., Sellares J., Sis B., et al. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012, 12:1180-1191.
101. Hidalgo L.G., Sis B., Sellares J., et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010, 10:1812-1822.
102. Li F., Atz M.E., Reed E.F. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009, 21:557-562.
103. Hirohashi T., Chase C.M., Della Pelle P., et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012, 12:313-321.
104. Stegall M.D., Chedid M.F., Cornell L.D. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012, 8:670-678.
105. Tillou X., Poirier N., Le Bas-Bernardet S., et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010, 78:152-159.
106. Zheng X., Lian D., Wong A., et al. Novel small interfering RNA-containing solution protecting donor organs in heart transplantation. Circulation 2009, 120:1099-1107. [1 p following 1107].
107. Lewis A.G., Köhl G., Ma Q., et al. Pharmacological targeting of C5a receptors during organ preservation improves kidney graft survival. Clin Exp Immunol 2008, 153:117-126.
108. Patel H., Smith R.A.G., Sacks S.H., et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006, 17:1102-1111.
109. Varagunam M., Yaqoob M.M., Döhler B., et al. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 2009, 360:874-880.
110. Damman J., Daha M.R., Leuvenink H.G., et al. Association of complement C3 gene variants with renal transplant outcome of deceased cardiac dead donor kidneys. Am J Transplant 2012, 12:660-668.
111. Wahrmann M., Döhler B., Ruhenstroth A., et al. Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol 2011, 22:367-376.